Versatope Therapeutics Inc.
Lowell, MA
- UEI
- VSMPM3EGYYA6
- CAGE
- 7TEE7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 110 Canal St Fl 4, Lowell, MA 01852, USA
- Website
- versatope.com
- Founded
- 2017
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Recombinant outer membrane vesicles as a novel adjuvant for a malaria vaccine - abstract while vaccines are an… | National Institute of Allergy and Infectious Diseases | $6,999,190 | |
| Novel c. Difficile vaccine using nano-vesicle delivery system | National Institute of Allergy and Infectious Diseases | $299,928 | |
| To make an award under HHS-NIH-niaid-BAA2018 | National Institute of Allergy and Infectious Diseases | $16,754,610 | |
| Multivalent influenza vaccine using exosomes from probiotic e. Coli | Office of Financial Resources | $45,808 | |
| Multivalent influenza vaccine using recombinant outer membrane vesicles | National Institute of Allergy and Infectious Diseases | $224,974 |
About Versatope Therapeutics Inc.
Versatope Therapeutics Inc. is a for-profit biotechnology company that delivers immunity through customized nano-sized vesicles using synthetic biology, revolutionizing immunotherapy for infectious diseases and cancer. It was registered in SAM.gov in February 2017 as a corporate entity and for-profit organization.
Versatope Therapeutics Inc. was awarded a $21,256,273 definitive contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases in September 2019 to advance development of recombinant outer membrane vesicle-based vaccines as part of the Broad Agency Announcement 2018 program. This cost-plus-fixed-fee contract supports research to establish and improve biomedical knowledge on infectious diseases such as malaria through April 2027. No set-aside designation was applied to this award made under the NIH-NIAID-BAA2018 vehicle to the for-profit prime contractor located in Lowell, Massachusetts.
The National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $999,762 Project Grant in December 2023 to Versatope Therapeutics Inc. under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding will advance the development of Versatope's recombinant outer membrane vesicle (ROMV) platform as a novel adjuvant for a malaria vaccine. Key deliverables include preclinical studies, toxicology assessments, and manufacturing process development to ready the ROMV-based malaria vaccine candidate for eventual clinical evaluation. Additionally, Versatope received a $299,928 Project Grant from NIH NIAID in August 2020 for a novel C. difficile vaccine using a nano-vesicle delivery system, and a $45,808 Cooperative Agreement from CDC in September 2019 for a multivalent influenza vaccine using exosomes from probiotic E. coli.
Quick answers
What is Versatope Therapeutics Inc.'s UEI?
Versatope Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is VSMPM3EGYYA6.
What is Versatope Therapeutics Inc.'s CAGE code?
Versatope Therapeutics Inc.'s CAGE code is 7TEE7.
What is Versatope Therapeutics Inc.'s primary NAICS code?
Versatope Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Versatope Therapeutics Inc. located?
Versatope Therapeutics Inc.'s physical address in SAM.gov is 110 Canal St Fl 4, Lowell, MA 01852, USA.
Is Versatope Therapeutics Inc. registered in SAM.gov?
Yes. Versatope Therapeutics Inc.'s SAM.gov registration is active through September 16, 2027.
What is Versatope Therapeutics Inc.'s most recent federal award?
Versatope Therapeutics Inc.'s most recent federal grant award is Recombinant outer membrane vesicles as a novel adjuvant for a malaria vaccine - abstract while vaccines are an… (R44AI181242), from National Institute of Allergy and Infectious Diseases, on December 8, 2023.
On GovTribe
See Versatope Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors